Qiagen Completes SAB Buy; Added to Nasdaq-100 | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen has completed its acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels, for around $90 million.

Qiagen announced the deal in early November, saying at that time that it expects SABiosciences' products to be highly synergistic with its September acquisition of UK-based companion diagnostics firm DxS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.